



Amendments to the Claims:





This listing of claims replaces all prior versions and listings of claims in the application:



Listing of Claims:

1. – 102. (Cancelled).


103. (New) A pharmaceutically acceptable salt of a diagnostic imaging contrast agent having a structure selected from the group consisting of:








104. (New) The pharmaceutically acceptable salt of claim 103, wherein the salt is selected from the group consisting of calcium, sodium, N-methyl-glucamine, and mixtures thereof.
105. (New) The pharmaceutically acceptable salt of claim 103, wherein the diagnostic imaging contrast agent has the structure:




106. (New) The pharmaceutically acceptable salt of claim 103, wherein the diagnostic imaging contrast agent has the structure:




, wherein Ph is phenyl, and wherein the salt is N-methyl-glucamine.

107. (New) The pharmaceutically acceptable salt of claim 103, wherein the diagnostic imaging contrast agent has the structure:




, wherein Ph is phenyl, and wherein the salt is a mixture of sodium and N-methyl-glucamine.


108. (New) A chelating ligand having the structure:




109. (New) A chelating ligand having the structure:




110. (New) A chelating ligand having the structure:




111. (New) A chelating ligand having the structure:



112. (New) A chelating ligand having the structure:



113. (New) A chelating ligand having the structure:



116. (New) A pharmaceutically acceptable salt of a chelating ligand according to any of claims 108-115.

117. (New) The pharmaceutically acceptable salt of claim 112, wherein the salt is selected from the group consisting of calcium, sodium, N-methyl-glucamine, and mixtures thereof.